UBS ASSET MANAGEMENT AMERICAS LLC - VERVE THERAPEUTICS INC ownership

VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 93 filers reported holding VERVE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 4.42 and the average weighting 0.3%.

Quarter-by-quarter ownership
UBS ASSET MANAGEMENT AMERICAS LLC ownership history of VERVE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$617,811
+90.3%
46,592
+106.9%
0.00%
Q2 2023$324,6660.0%22,5150.0%0.00%
Q1 2023$324,666
-21.4%
22,515
+5.4%
0.00%
Q4 2022$413,219
-100.0%
21,355
-22.4%
0.00%
-100.0%
Q3 2022$944,694,000
+312.2%
27,502
+83.3%
0.00%
Q2 2022$229,200,000
-23.3%
15,000
+85.2%
0.00%
Q4 2021$298,647,0008,1000.00%
Other shareholders
VERVE THERAPEUTICS INC shareholders Q1 2022
NameSharesValueWeighting ↓
ARCH Venture Management, LLC 2,008,809$26,636,80717.30%
Alphabet Inc. 10,549,086$139,880,8808.98%
Casdin Capital, LLC 2,954,710$39,179,4554.34%
MPM BioImpact LLC 857,940$11,376,2843.04%
Saltoro Capital, LP 66,500$881,7900.79%
ARK Investment Management 5,200,567$68,959,5250.53%
Redmile Group, LLC 809,777$10,737,6430.51%
Ikarian Capital, LLC 2,413$3,199,6380.38%
Logos Global Management LP 215,000$2,850,9000.38%
Nikko Asset Management Americas, Inc. 2,147,243$28,429,4970.34%
View complete list of VERVE THERAPEUTICS INC shareholders